Recent news on Iodixanol

N-acetylcysteine plus sodium bicarbonate best bet for preventing ...  -  Feb 22, 2007
TheHeart.Org,All of the study participants also received iodixanol, an iso-osmolar, nonionic contrast agent, and all were at medium to high risk of contrast nephropathy,

Low-osmolarity contrast agents equivalent to iso-osmolar agents ...  Oct 25, 2006
In these latest studies, treatment with iodixanol, an iso-osmolar, nonionic contrast agent, was not associated with a reduction in the incidence of contrast ... -TheHeart.Org, The Latest Head-to-Head Clinical Study Comparing the Risk of CIN ...  Nov 1, 2006
...in the United States, and Visipaque(TM)-320 (iodixanol injection), marketed by GE Healthcare in the United States, in renally Impaired Patients undergoing ... -PharmaLive.com (press release), Guerbet - Another Proof That There is no Difference Between Low ...  Oct 27, 2006
October 27 /PRNewswire/ -- Results from a recent clinical trial demonstrated that contrast agents Hexabrix® (Ioxaglate) and Visipaque® (Iodixanol) were no ... -Yahoo! News (press release) Guerbet - Another Proof That There is no Difference Between Low ...  Oct 27, 2006
Results from a recent clinical trial demonstrated that contrast agents Hexabrix(R) (Ioxaglate) and Visipaque(R) (Iodixanol) were no different in regard to ... -netPR.pl (komunikaty prasowe), Guerbet - Another Proof That There is no Difference Between Low ...  Oct 27, 2006
27, 2006 /PRNewswire/ -- Results from a recent clinical trial demonstrated that contrast agents Hexabrix(R) (Ioxaglate) and Visipaque(R) (Iodixanol) were no ... -PharmaLive.com (press release), TCT: Low-Osmolar Contrast Agents Don't Increase Nephropathy Risk  Oct 26, 2006
26 -- The use of Visipaque (iodixanol), an iso-osmolar, nonionic contrast agent, did not reduce the rate of nephropathy in angiography patients with renal ... -MedPage Today, GE Healthcare Collaborates With Manipal Health Systems to Conduct ...  Jun 29, 2006
The first studies will focus on Visipaque(TM) (iodixanol) an isosmolar contrast agent that was launched globally by GE Healthcare in 1996. ... -News2UNet (プレスリリース)

GE opens development centre in India to study medical diagnostic ...  Jul 13, 2006
The first studies will focus on Visipaque (iodixanol) an isosmolar contrast agent that was launched globally by GE Healthcare in 1996. ... -MTBeurope

COMUNICADO: GE Healthcare Collaborates With Manipal Health Systems ...  Jun 29, 2006
An isotonic, aqueous solution containing iodixanol, a non-ionic, dimeric contrast medium, available in three strengths containing either 150 mg, 270 mg or 320 ... -Europa Press

Hybrid Imaging, Part 1: Daybreak for a New Radiology  Jan 25, 2006
...followed by serial IV contrast CT scans that were obtained at 30 seconds, 70 seconds, and 180 seconds after IV contrast administration (150 mL iodixanol, 320 mg ... - Medscape (subscription)

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional